Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03616483 · ClinicalTrials.gov registry record
The Indiana Myeloma Registry
A clinical trial of Plasma Cell Dyscrasias, sponsored by Indiana University.
- Recruiting
- Registry status
- 2,500
- Enrollment target
- 1
- Study location
NCT03616483 is a study of Plasma Cell Dyscrasias that is actively recruiting participants, run by Indiana University. The registered enrollment target is 2,500 participants. The trial reports 1 study location across 1 state.
The verdict
NCT03616483, a study of Plasma Cell Dyscrasias, is actively recruiting participants, sponsored by Indiana University.
- RECRUITING
- Registry status
- 2,500 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a prospective, non-interventional, observational study. The purpose of this study is to collect data and bio-specimens that will support future research
Conditions Studied
Interventions
- OTHER This is a non-interventional trial
Study Locations (1)
Indiana
- Indiana University Simon Cancer Center - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,500 participants |
| Start Date | 2018-06-18 |
| Est. Completion | 2028-06-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03616483
The ClinicalTrials.gov registry entry for NCT03616483 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 2,500 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Indiana University, which has 890 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Plasma Cell Dyscrasias appearing as the primary indexed condition, and to 1 intervention - of which This is a non-interventional trial is the first listed.
NCT03616483 reports 1 study location spanning 1 distinct geographic area - top geographies include Indiana.
Frequently Asked Questions
What is clinical trial NCT03616483 about?
NCT03616483 is a clinical study titled "The Indiana Myeloma Registry". This is a prospective, non-interventional, observational study. The purpose of this study is to collect data and bio-specimens that will support future research
What is the current status of trial NCT03616483?
This trial is currently recruiting. The enrollment target is 2,500 participants. The study started on 2018-06-18. Estimated completion is 2028-06-30.
What conditions does trial NCT03616483 study?
This clinical trial studies the following conditions: Plasma Cell Dyscrasias.
What interventions are being tested in trial NCT03616483?
The interventions under investigation include: This is a non-interventional trial (OTHER).
Who is sponsoring clinical trial NCT03616483?
This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03616483 being conducted?
This trial has 1 study location across Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Plasma Cell Dyscrasias
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.